EA200200562A1 - Антагонисты аденозиновых рецепторов и способы их получения и использования - Google Patents

Антагонисты аденозиновых рецепторов и способы их получения и использования

Info

Publication number
EA200200562A1
EA200200562A1 EA200200562A EA200200562A EA200200562A1 EA 200200562 A1 EA200200562 A1 EA 200200562A1 EA 200200562 A EA200200562 A EA 200200562A EA 200200562 A EA200200562 A EA 200200562A EA 200200562 A1 EA200200562 A1 EA 200200562A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
adenose
receptors
reception
methods
Prior art date
Application number
EA200200562A
Other languages
English (en)
Other versions
EA010260B1 (ru
Inventor
Джеймс Е. Даулинг
Кэрол Энсингер
Гнанасамбандам Кумаравел
Расселл С. Петтер
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200200562A1 publication Critical patent/EA200200562A1/ru
Publication of EA010260B1 publication Critical patent/EA010260B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение основано на неожиданном обнаружении того факта, что соединения формулы I являются сильнодействующими и селективными ингибиторами аденозинового рецептора A. Антагонисты аденозина Aмогут быть использованы для предупреждения и/или лечения многих заболеваний, включая нарушение работы сердца и кровообращения, дегенеративные расстройства центральной нервной системы, заболевания дыхательных путей и многие заболевания, для которых показано лечение диуретиками. В одном из своих вариантов настоящее изобретение относится к соединению формулы (I).Отчет о международном поиске был опубликован 2002.01.10.
EA200200562A 1999-11-12 2000-11-13 Антагонисты аденозиновых рецепторов и способы их получения и использования EA010260B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (2)

Publication Number Publication Date
EA200200562A1 true EA200200562A1 (ru) 2002-10-31
EA010260B1 EA010260B1 (ru) 2008-06-30

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200562A EA010260B1 (ru) 1999-11-12 2000-11-13 Антагонисты аденозиновых рецепторов и способы их получения и использования

Country Status (33)

Country Link
US (4) US6605600B1 (ru)
EP (2) EP1230241B1 (ru)
JP (1) JP2003513976A (ru)
KR (1) KR100845488B1 (ru)
CN (1) CN1187354C (ru)
AT (1) ATE353328T1 (ru)
AU (1) AU784528B2 (ru)
BG (1) BG106693A (ru)
BR (1) BR0015540A (ru)
CA (1) CA2390590C (ru)
CY (1) CY1106560T1 (ru)
CZ (1) CZ20021615A3 (ru)
DE (1) DE60033310T2 (ru)
DK (1) DK1230241T3 (ru)
EA (1) EA010260B1 (ru)
EE (1) EE200200248A (ru)
ES (1) ES2281367T3 (ru)
GE (1) GEP20043267B (ru)
HK (1) HK1049153B (ru)
HU (1) HUP0203371A3 (ru)
IL (1) IL149486A0 (ru)
IS (1) IS6380A (ru)
MX (1) MXPA02004795A (ru)
NO (1) NO20022237L (ru)
NZ (2) NZ519427A (ru)
PL (1) PL198156B1 (ru)
PT (1) PT1230241E (ru)
SK (1) SK6622002A3 (ru)
TR (1) TR200301062T2 (ru)
UA (1) UA77937C2 (ru)
WO (1) WO2001034604A2 (ru)
YU (1) YU33702A (ru)
ZA (1) ZA200203702B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GEP20043267B (en) * 1999-11-12 2004-06-25 Biogen Inc Us Adenosine Receptor Antagonists, Methods of Making and Using the Same
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina
BR0312137A (pt) * 2002-06-12 2005-04-05 Mcw Res Found Inc Processo de tratamento de dano de reperfusão de isquemia usando antagonistas de receptor de adenosina
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004089908A2 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives
WO2004096228A1 (en) * 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
CN102516241B (zh) 2006-05-19 2015-07-29 艾伯维巴哈马有限公司 Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JP2988711B2 (ja) 1989-10-20 1999-12-13 協和醗酵工業株式会社 縮合プリン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
DE69229257D1 (de) 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
US5336769A (en) 1992-02-17 1994-08-09 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (ru) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
AU7675598A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Hepatic edema remedy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
WO2000001388A1 (fr) 1998-07-02 2000-01-13 Kyowa Hakko Kogyo Co., Ltd. Medicaments antidiabetiques
GEP20043267B (en) * 1999-11-12 2004-06-25 Biogen Inc Us Adenosine Receptor Antagonists, Methods of Making and Using the Same
PT1230243E (pt) * 1999-11-12 2009-06-12 Biogen Idec Inc Policicloalquilpurinas como antagonistas dos receptores da adenosina

Also Published As

Publication number Publication date
UA77937C2 (en) 2007-02-15
US20080004293A1 (en) 2008-01-03
NO20022237L (no) 2002-07-12
KR100845488B1 (ko) 2008-07-10
HK1049153A1 (en) 2003-05-02
EA010260B1 (ru) 2008-06-30
HUP0203371A2 (hu) 2003-02-28
US20050222179A1 (en) 2005-10-06
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
ES2281367T3 (es) 2007-10-01
CY1106560T1 (el) 2012-01-25
YU33702A (sh) 2005-03-15
DE60033310T2 (de) 2007-11-22
PT1230241E (pt) 2007-05-31
BG106693A (bg) 2003-01-31
CN1399636A (zh) 2003-02-26
GEP20043267B (en) 2004-06-25
ATE353328T1 (de) 2007-02-15
WO2001034604A2 (en) 2001-05-17
DK1230241T3 (da) 2007-06-04
EP1775297A2 (en) 2007-04-18
KR20020049043A (ko) 2002-06-24
EP1230241B1 (en) 2007-02-07
BR0015540A (pt) 2002-07-23
SK6622002A3 (en) 2003-02-04
CA2390590A1 (en) 2001-05-17
IL149486A0 (en) 2002-11-10
EE200200248A (et) 2003-06-16
AU2042101A (en) 2001-06-06
EP1230241A2 (en) 2002-08-14
MXPA02004795A (es) 2005-07-01
HK1049153B (zh) 2007-09-28
PL356044A1 (en) 2004-06-14
HUP0203371A3 (en) 2005-02-28
IS6380A (is) 2002-05-10
CN1187354C (zh) 2005-02-02
NZ527918A (en) 2005-05-27
JP2003513976A (ja) 2003-04-15
AU784528B2 (en) 2006-04-27
US20030225038A1 (en) 2003-12-04
US6605600B1 (en) 2003-08-12
PL198156B1 (pl) 2008-05-30
CA2390590C (en) 2010-03-16
WO2001034604A3 (en) 2002-01-10
DE60033310D1 (de) 2007-03-22
ZA200203702B (en) 2003-10-29
CZ20021615A3 (cs) 2002-08-14
NZ519427A (en) 2003-08-29
EP1775297A3 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
EE200200247A (et) Polütsükloalküülpuriinid kui adenosiiniretseptoriantagonistid
RS20050041A (en) Azaindole kinase inhibitors
TR200103352T2 (tr) Kinas pirolotriazin inhibitörleri
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
IS8096A (is) Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы
TH51180A (th) วิธีสำหรับการรักษาโรคพาร์คินสันโดยการให้ (-)-5- คีโท-2-N,N-ได-n-โปรพิลอะมิโน-เตตระไฮโดรเตตระลิน
TH13960EX (th) สารละลายโซมาโตโพรพินที่เข้ากันได้ในทางชีววิทยา
RU93004718A (ru) Гетероциклические производные, способ их получения, применение, способ лечения, фармацевтическая композиция

Legal Events

Date Code Title Description
HC1A Change in name of an applicant in a eurasian application
FA9A Withdrawal of a eurasian application
NF9A Restoration of lapsed right to a eurasian application

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU